Loading...

Bio-Rad Laboratories, Inc.

BIO-BNYSE
Healthcare
Medical - Devices
$257.75
$7.67(3.07%)

Bio-Rad Laboratories, Inc. (BIO-B) Stock Overview

Explore Bio-Rad Laboratories, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 68.0/100

Key Financials

Market Cap7B
P/E Ratio-3.23
EPS (TTM)$-76.53
ROE-0.32%
Fundamental Analysis

AI Price Forecasts

1 Week$258.20
1 Month$258.97
3 Months$340.39
1 Year Target$268.65

BIO-B Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Bio-Rad Laboratories, Inc. (BIO-B) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 100.00, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $268.65.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -3.23 and a market capitalization of 7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

100.00RSI (14)
6.07MACD
100.00ADX
Revenue Growth
-3.92%
3.92%
Profit Growth
$-79.74
189.37%
EPS Growth
$-79.74
199.54%
Operating Margin
9.71%
20.37%
ROE
-32.39%
189.37%
Dividend Yield
0.00%
Analyst Recommendations data is not available for BIO-BAnalyst Recommendations details for BIO-B are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

CEO

Norman D. Schwartz

Employees

7,700

Headquarters

1000 Alfred Nobel Drive, Hercules, CA

Founded

1999

Frequently Asked Questions

;